Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:50 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05083208 · Henan Cancer Hospital · PHASE1 · terminated · last registry update 2025-12-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The clinical development of parsaclisib was stopped by it's manufacturer.” | – | Registry record, Henan Cancer Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CD within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-30Results posted on the registry: Alliance for Clinical Trials in Oncology, Abemaciclib + PI3K Inhibitor paxalisib (NCT03994796)
- 2026-10-27Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Ipilimumab (NCT04317105)
- 2026-10-21Results posted on the registry: Incyte Biosciences Japan GK, tafasitamab + lenalidomide (NCT04661007)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-03-30Results posted on the registry: Pharming Technologies B.V., CDZ173 (NCT02859727)
- 2026-03-30Also stopped (terminated): Pharming Technologies B.V., CDZ173 (NCT02859727)
- 2026-03-03Results posted on the registry: National Cancer Institute (NCI), Rituximab + Copanlisib (NCT03789240)
- 2026-02-27Results posted on the registry: Massachusetts General Hospital, Umbralisib + Rituximab (NCT03919175)
- 2026-02-27Also stopped (terminated): Massachusetts General Hospital, Umbralisib + Rituximab (NCT03919175)
- 2026-02-13Also stopped (suspended): Dana-Farber Cancer Institute, Palbociclib + Gedatolisib (NCT03065062)
- 2026-02-04Also stopped (terminated): Incyte Corporation, tafasitamab + parsaclisib (NCT04809467)
- 2026-02-04Also stopped (terminated): Centre Hospitalier Universitaire Dijon, Taselisib (GDC0032) + Taselisib (GDC0032) (NCT03290092)
- 2026-01-29Results posted on the registry: Incyte Corporation, tafasitamab + parsaclisib (NCT04809467)
- 2026-01-09Also stopped (terminated): M.D. Anderson Cancer Center, Copanlisib + fulvestrant (NCT05082025)
- 2026-01-06Also stopped (terminated): H. Lee Moffitt Cancer Center and Research Institute, Umbralisib (NCT04163718)
- 2025-11-03Also stopped (terminated): Incyte Corporation, parsaclisinib + placebo (NCT05073458)
- 2025-10-21Also stopped (terminated): Incyte Corporation, parsaclisib + ruxolitinib (NCT04551066)
- 2025-10-02Also stopped (terminated): Incyte Corporation, parsaclisib + ruxolitinib (NCT04551053)
- 2025-10-01Also stopped (terminated): National Cancer Institute (NCI), Copanlisib + Pertuzumab (NCT04108858)
- 2025-09-08Also stopped (terminated): Institut Curie, PF-05212384 (NCT02438761)
- 2025-08-24Phase 3 first posted: Dizal Pharmaceuticals, DZD8586 + Bendamustine (NCT07139873)
- 2025-08-08Also stopped (terminated): Fondazione Italiana Linfomi - ETS, Copanlisib (NCT04433182)
- 2025-08-03Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Durvalumab (NCT03842228)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Eribulin Mesylate (NCT04345913)
- 2025-07-22Also stopped (terminated): Cancer Trials Ireland, Copanlisib + Trastuzumab emtansine (NCT04042051)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision